Sepsis (peds)

(Redirected from Sepsis (Peds))

This page is for adult patients. For pediatric patients, see: Sepsis.

Background

  • Defined as a dysregulated host response to infection that leads to life-threatening organ dysfunction[1]
  • Tachycardia is typically most predominant, hypotension is a late and ominous sign

Clinical Features

Shock: Warm vs Cold Shock

Warm Shock Cold Shock
Peripheries Warm, Flushed Mottled, Cold, Clammy
Cap Refill <2 sec >2 sec
Pulse Bounding Weak, Thready
BP Compensated Hypotension
HR Tachy Tachy or Brady
Pulse Pressure Widen Narrow

Neonatal Sepsis

  • Early onset
    • First few days of life
    • Fulminant, associated with maternal or perinatal risk factors
    • Septic shock and neutropenia are more common
  • Late onset
    • Occurs after 1 week of age
    • Gradual
    • Meningitis more likely
  • Consider if feeding disturbance, rash, lethargy, irritability, seizure, apnea, tachypnea, grunting, vomiting, poor PO, gastric distention, diarrhea

Differential Diagnosis

Sick Neonate

THE MISFITS [2]

Pediatric fever

Evaluation

Work-Up

Diagnosis

  • Initial screening and decision to send studies is based on provider judgement
  • Use the Phoenix Sepsis Score to calculate sepsis criteria, including septic shock.[3][4]
    • Not indicated for adults, preterm (<37 weeks), or peri-birth hospitalizations

Management

Initial Resuscitation Focus

  1. Treat hypoxemia with supplemental oxygen (goal SpO2 92-98%)[5]
  2. Obtain intravenous/intraosseous access
    • Rapidly transition to IO access, if difficulties with starting IV
  3. Collect diagnostic tests (including blood culture, lactate, ionized calcium; see workup above)
  4. Early empiric broad-spectrum antibiotics (see below)
  5. Administer bolus intravenous fluid therapy administration (see below), if shock is present
  6. Start vasoactive agents, if shock persists
  7. Airway
    • Consider CPAP (may buy time for fluid resuscitation prior intubation)
    • Consider intubation, especially in fluid refractory shock
      • Consider use of ketamine for sedation (less hypotension)
      • Be prepared for cardiovascular collapse
  8. Consider corticosteroids[6]
  9. Continue to reassess (see below)

Empiric Broad-Spectrum Antibiotics

If in shock, administer as soon as possible. If not, it is reasonable to perform expedited diagnostics before administration.[7]

Neonatal

Peds

Treatment will differ by local protocols

OR

OR

Fluid Resuscitation

  • For shock, 20 mL/kg boluses of isotonic crystalloid fluid titrated to clinical markers of cardiac output[8]
    • Frequently ≥40 mL/kg in the first hour of resuscitation
  • In low-resource settings (e.g., low income countries), fluid bolus therapy should be avoided unless the child exhibits hypotension[9]

Vasopressors

Corticosteroids

  • Intravenous hydrocortisone recommended only for children with fluid-refractory, catecholamine-resistant shock.[14]
    • There are no data on the addition of fludrocortisone to enhance the mineralocorticoid effect in pediatric septic shock.[15]

Reevaluation

  • Patients should be continuously reassessed for signs of:
    • Ongoing or worsening shock
    • Iatrogenic fluid overload (e.g., pulmonary rales, hepatomegaly, peripheral edema, and echocardiographic findings that may suggest fluid overload)
  • Golden Hour Goals
    • Cap refill <2 sec
    • Normal BP
    • Normal pulses, similar central and peripheral
    • Warm extremities
    • UOP >1 mL/kg/hr
    • Normal mental status

Disposition

  • Admit

See Also

External Links

References

  1. Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics (2024) 153 (1): e2023062967. https://doi.org/10.1542/peds.2023-062967
  2. Brousseau T, Sharieff GQ. Newborn emergencies: the first 30 days of life. Pediatr Clin North Am. 2006 Feb;53(1):69-84, vi.
  3. Schlapbach LJ, et al. International Consensus Criteria for Pediatric Sepsis and Septic Shock. JAMA. 2024 Feb 27;331(8):665-674. doi: 10.1001/jama.2024.0179.
  4. Sanchez-Pinto LN, et al. Development and Validation of the Phoenix Criteria for Pediatric Sepsis and Septic Shock. JAMA. 2024 Feb 27;331(8):675-686. doi: 10.1001/jama.2024.0196.
  5. Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics (2024) 153 (1): e2023062967. https://doi.org/10.1542/peds.2023-062967
  6. Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics (2024) 153 (1): e2023062967. https://doi.org/10.1542/peds.2023-062967
  7. Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics (2024) 153 (1): e2023062967. https://doi.org/10.1542/peds.2023-062967
  8. Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics (2024) 153 (1): e2023062967. https://doi.org/10.1542/peds.2023-062967
  9. Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics (2024) 153 (1): e2023062967. https://doi.org/10.1542/peds.2023-062967
  10. Marik PE. Dopamine increases mortality in pediatric septic shock. Journal of Pediatrics. January 2016, Volume 168, Pages 253–256.
  11. Ventura AM, Shieh HH, Bousso A, Goes PF, Fernandes IC, de Souza DC, et al. Double-Blind Prospective Randomized Controlled Trial of Dopamine Versus Epinephrineas First-Line Vasoactive Drugs in Pediatric Septic Shock. Crit Care Med 2015;43:2292-302.
  12. Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics (2024) 153 (1): e2023062967. https://doi.org/10.1542/peds.2023-062967
  13. Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics (2024) 153 (1): e2023062967. https://doi.org/10.1542/peds.2023-062967
  14. Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics (2024) 153 (1): e2023062967. https://doi.org/10.1542/peds.2023-062967
  15. Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics (2024) 153 (1): e2023062967. https://doi.org/10.1542/peds.2023-062967